ArticleNephro-urology monthly2014
Effect of spironolactone on diabetic nephropathy compared to the combination of spironolactone and losartan.
Article in Nephro-urology monthly, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.The Cochrane database of systematic reviews · 2020Pooled it
- Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy.Journal of diabetes investigation · 2017Pooled it
- Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population.BMC research notes · 2016Trial
- Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease.Drug delivery · 2023Article
- Organoprotective Effects of Spironolactone on Top of Ramipril Therapy in a Mouse Model for Alport Syndrome.Journal of clinical medicine · 2021Article
- Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity.Frontiers in physiology · 2021Review
- Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease.Frontiers in pharmacology · 2021Review
- Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes.International urology and nephrology · 2019Article
- The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy.Current clinical pharmacology · 2019Review
- Reporting Quality Assessment of Randomized Controlled Trials Published in Nephrology Urology Monthly Journal.Nephro-urology monthly · 2015Review
- Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy.Journal of diabetes research · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic nephropathy is the most important cause of end stage renal disease (ESRD). Aldosterone is involved in renal damage through induction of fibrosis, inflammation and necrosis in the kidney tissue. Previous studies have demonstrated that the combination of angiotensin receptor blocker (ARB) and spironolactone (an anti-aldosterone drug) are efficient for albuminuria reduction.
objectivesThis study was designed to evaluate the effect of spironolactone alone on diabetic nephropathy. PATIENTS AND
methodsIn this double blind randomized clinical trial, 60 type II diabetic patients with microalbuminuria were enrolled. They were divided into two groups: case group (spironolactone 25 mg and placebo, 30 cases) and control (spironolactone 25 mg plus losartan 25 mg, 30 cases). The treatment success rate (more than 50% reduction in microalbuminuria) was compared between the two groups.
resultsAfter three months, successful treatment was seen in 70% (95% CI: 52 - 83) and 83.3% (CI 95%: 66 - 93) of case and control groups, respectively (P = 0.4). Mean ± SD of serum potassium levels after three months in case and control groups were 4.56 ± 0.38 and 4.39 ± 0.34 mEq/L, respectively (P = 0.08). Mean ± SD of systolic blood pressures in case and control groups were 129.67 ± 9.4 and 130.97 ± 9.4 mmHg, respectively (P = 0.6). Mean ± SD of serum creatinine levels at the end of the study were 0.95 ± 0.15 in case and 0.90 ± 0.22 mg/dL in control group (P = 0.4).
conclusionsSpironolactone alone is as effective as the combination of spironolactone and losartan on albuminuria reduction in type 2 diabetic patients and can be used alone as an effective drug for diabetic nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.